

*Sub B
contd*

A

3. (Amended) A composition according to claim 1, wherein the distressing substance is selected from the group consisting of emetics, nauseants and flavouring or bitter substances.

4. (Amended) A composition according to claim 3, wherein the distressing substance is selected from the group consisting of ergolides; quaternary ammonium compounds; non-permeant opioid antagonists; other opioid antagonists; emetics; and atropine or salts thereof.

A

5. (Amended) A composition according to claim 1, wherein the distressing substance is non-permeant and is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

6. (Amended) A composition according to claim 1, wherein the opioid analgesic is selected from the group consisting of morphine, hydromorphone, buprenorphine, ketamine, fentanyl, tramadol, or pharmaceutically acceptable and percutaneously transmissible salts thereof.

A

7. (Amended) A composition according to claim 1 wherein the opioid analgesic is a narcotic opioid analgesic.

A

8. (Amended) A composition according to claim 1, wherein the opioid analgesic is in an aqueous and/or alcoholic solution, or incorporated in a matrix including a pressure sensitive adhesive.

9. (Amended) A transdermal device containing a composition according to claim 1.

10. (Amended) A device according to claim 10, which is a monolithic patch.

A

11. (Amended) A composition according to claim 1, which contains buprenorphine or pharmaceutically acceptable salt thereof as the opioid analgesic and atropine or pharmaceutically